APOC3 and hypertriglyceridemia: Considering that the most recent approaches to manage severe forms of hypertriglyceridemia by means of the antagonism of apo C-III or of ANGPLT3 are far from to be clinically available, the use of icosapent ethyl or pemafibrate [123] becomes of high interest.